[go: up one dir, main page]

PL1904048T3 - Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych - Google Patents

Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych

Info

Publication number
PL1904048T3
PL1904048T3 PL06777795T PL06777795T PL1904048T3 PL 1904048 T3 PL1904048 T3 PL 1904048T3 PL 06777795 T PL06777795 T PL 06777795T PL 06777795 T PL06777795 T PL 06777795T PL 1904048 T3 PL1904048 T3 PL 1904048T3
Authority
PL
Poland
Prior art keywords
glepp
autoimmune
treatment
inhibitors
inflammatory disorders
Prior art date
Application number
PL06777795T
Other languages
English (en)
Inventor
Agnes Bombrun
Van Huijsduijnen Rob Hooft
Catherine Jorand-Lebrun
Pierre-Alain Vitte
Patrick Gerber
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of PL1904048T3 publication Critical patent/PL1904048T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06777795T 2005-07-15 2006-07-14 Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych PL1904048T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05106547 2005-07-15
US70636505P 2005-08-08 2005-08-08
PCT/EP2006/064288 WO2007009959A1 (en) 2005-07-15 2006-07-14 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
EP06777795A EP1904048B1 (en) 2005-07-15 2006-07-14 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders

Publications (1)

Publication Number Publication Date
PL1904048T3 true PL1904048T3 (pl) 2012-04-30

Family

ID=35423337

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06777795T PL1904048T3 (pl) 2005-07-15 2006-07-14 Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych

Country Status (24)

Country Link
US (1) US20080207722A1 (pl)
EP (1) EP1904048B1 (pl)
JP (1) JP2009501197A (pl)
KR (1) KR20080036084A (pl)
CN (1) CN101282719A (pl)
AT (1) ATE534380T1 (pl)
AU (1) AU2006271682B2 (pl)
BR (1) BRPI0613400A2 (pl)
CA (1) CA2609929A1 (pl)
CY (1) CY1112148T1 (pl)
DK (1) DK1904048T3 (pl)
EA (1) EA200800342A1 (pl)
ES (1) ES2377881T3 (pl)
HR (1) HRP20110875T1 (pl)
IL (1) IL188735A (pl)
MX (1) MX2008000665A (pl)
NO (1) NO20080781L (pl)
PL (1) PL1904048T3 (pl)
PT (1) PT1904048E (pl)
RS (1) RS52116B (pl)
SI (1) SI1904048T1 (pl)
UA (1) UA94049C2 (pl)
WO (1) WO2007009959A1 (pl)
ZA (1) ZA200710497B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CN103561573A (zh) * 2011-04-26 2014-02-05 印第安纳大学研究与技术公司 酪氨酸磷酸酶及其在调节参与结核分枝杆菌之病理学的酶的活性中的用途
BR112018012825A2 (pt) * 2015-12-22 2018-12-04 Syngenta Participations Ag derivados de oxadiazol microbiocidas
CN107936110B (zh) * 2017-11-07 2021-06-22 潍坊医学院 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制
EP4132523A4 (en) * 2020-04-06 2024-05-15 Purdue Research Foundation Novel n-aryl oxamic acids
EP4470534A1 (en) * 2022-01-27 2024-12-04 Vivozon, Inc. Pharmaceutical composition for preventing or treating mental disorder
CN118239851B (zh) * 2024-03-20 2025-07-25 蚌埠医科大学 一种ptpro抑制剂的制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
EP0727406B1 (de) * 1995-02-16 2001-09-05 MERCK PATENT GmbH Vinylenverbindungen und flüssigkristallines Medium
AU5347496A (en) * 1995-04-21 1996-11-07 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
FR2762514B1 (fr) * 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
CA2463615C (en) * 2001-10-30 2011-07-26 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
JP2003171305A (ja) * 2001-11-30 2003-06-20 Yunie:Kk 糖尿病改善治療剤
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
MXPA04007253A (es) * 2002-01-29 2004-10-29 Applied Research Systems Derivados de metilenamidas sustituidos como moduladores de proteina tirosina fosfatasas (ptp).
JP2006523196A (ja) 2003-03-11 2006-10-12 ニューロサーチ、アクティーゼルスカブ 新規kcnqチャネルを調節する化合物及びその医薬用途
JP5198768B2 (ja) * 2003-07-21 2013-05-15 メルク セローノ ソシエテ アノニム アルキニルアリールカルボキサミド
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
BRPI0508790A (pt) * 2004-04-07 2007-09-04 Applied Research Systems ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário

Also Published As

Publication number Publication date
AU2006271682B2 (en) 2012-07-05
CN101282719A (zh) 2008-10-08
PT1904048E (pt) 2011-12-19
CY1112148T1 (el) 2015-11-04
ATE534380T1 (de) 2011-12-15
EP1904048A1 (en) 2008-04-02
IL188735A (en) 2012-07-31
UA94049C2 (ru) 2011-04-11
EA200800342A1 (ru) 2008-08-29
NO20080781L (no) 2008-02-13
US20080207722A1 (en) 2008-08-28
AU2006271682A1 (en) 2007-01-25
ZA200710497B (en) 2009-04-29
ES2377881T3 (es) 2012-04-02
CA2609929A1 (en) 2007-01-25
EP1904048B1 (en) 2011-11-23
JP2009501197A (ja) 2009-01-15
BRPI0613400A2 (pt) 2011-01-11
KR20080036084A (ko) 2008-04-24
RS52116B (sr) 2012-08-31
HRP20110875T1 (hr) 2011-12-31
IL188735A0 (en) 2008-12-29
WO2007009959A1 (en) 2007-01-25
DK1904048T3 (da) 2011-12-19
SI1904048T1 (sl) 2012-01-31
MX2008000665A (es) 2008-03-13

Similar Documents

Publication Publication Date Title
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
PL2288372T3 (pl) Mutant IL-2 do zastosowania w leczeniu lub profilaktyce choroby autoimmunizacyjnej
NO20082907L (no) Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer
NO20083492L (no) 11-Beta HSD1 inhibitorer
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
EP1885388A4 (en) TREATMENT AND ASSESSMENT OF INFLAMMATORY DISEASES
JO3358B1 (ar) معالجات حساسية العيون
MX2010008397A (es) Inhibidores del receptor de quimioquinas cxcr3.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
DK1651234T3 (da) Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser
PL3972604T3 (pl) Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
DE602008005786D1 (de) C-met-proteinkinasehemmer
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
WO2006057997A3 (en) Plasmin-inhibitory therapies
MA32474B1 (fr) Nouveaux derives de (piperazinyl ponte) -1-alcanone et leur utilisation comme inhibiteurs de p75
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
WO2019115493A3 (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EP1909784A4 (en) CYSTEIN PROTEASE HEMMER OF THE PAPAIN FAMILY FOR THE TREATMENT OF PARASITIC ILLNESSES
MA33555B1 (fr) Procédés et compositions pour traiter la leucémie